- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02319395
Behavioural Addiction and Genetics in Parkinson's Disease (BADGE-PD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objective: To identify susceptibility genes to impulse control disorders in Parkinson's Disease.
Study design: Genetic association study.
Primary objective:
To identify the susceptibility genes in behavior addiction in Parkinson's Disease
Secondary endpoints:
- To compare the clinical, neurological and psychiatric features of parkinsonian patients with behavior addiction compared to the control population. In case of differences between these groups, interaction will be studied with genetic factors
- Identify a psychometric profile from the TCI-R scale corresponding to the "hyperdopaminergic" subjects with AC personality
Patient selection:
Cases: patients with Parkinson's disease (PD) and impulse control disorder (ICD) as defined by a score greater than or equal to 2 or 3 scores greater than or equal to 2 at the "Evaluation Comportementale de la Maladie de Parkinson" scale (ECMP, Ardouin et al. 2009) for hyperdopaminergic items.
Controls: PD patients without impulse control disorder (ICD) as defined by a score of 0 or 1 at each hyperdopaminergic items AND no more than 2 items with a score of 1. Controls must have been treated with at least 300 mg of Levodopa equivalent daily dose for more than 12 months. Controls will be matched for sex, age, and age at onset of PD.
Number of subjects: 200 cases and 200 controls.
Clinical assessment: motor score (UPDRS), neuropsychological assessment, diagnostic criteria for addiction and ICD (MINI), self-administered psychometric questionnaire (TCI-R), treatment history, ICD history.
Genetic analysis: A blood sample will be taken for extraction and storage of DNA (DNA bank and Pitie-Salpetriere cells). Candidate genes* and polymorphisms will be selected from the literature data (receptors, transporters and metabolizing enzymes monoamine) and the molecular signature induced by L-DOPA in the striatum of a mice model of PD.
Statistical analysis:
A two-step analysis will be performed. For the first step, a training set (36% of subjects) will be analyzed with a logistic regression model considering an additive genetic effect. For the second step, the top 27% of the more significant genetic markers will be analyzed by using the left over replication set (64% of patients). Finally, a pooled analysis will be performed.
Sample Size: 200 patients per group to study 50 candidate markers with a power of 83% for genotype effect of 2.0, an additive genetic model, each allele frequency of 0.5.
* candidate genes list:
20 genes from the literature : DRD1, ANKK1, DRD2, DRD3, DRD4, DAT1, MAOA, COMT, HTR2A, HTR1B, TPH1, TPH2, 5HTT, GRIN2B, DBH, SCL6A2, BDNF, OPMR1, OPRK1, PDYN 8 genes from the experimentation: FosB, Arc, Nptx2, Ccrn4l, Car12, C8b, Mocs1, Mef2c
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75013
- Groupe Hospitalier la Pitié Salpêtrière
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria :
Case Group
- Age upper or equal to 30 years
- Caucasian European (2 parents and 4 grandparents born in Europe)
- Parkinson's disease according to the criteria of UKPDSBB
With a behavioral addiction defined as:
- A score greater than or equal to 2 or 3 scores greater than or equal to 2 at hyperdopaminergic following items of Ardouin's scale (ECMP): eating behaviors, creativity, hobbyism, risk-taking behaviors, compulsive shopping, pathological gambling, hypersexuality, cyber-addiction, and Punding.
- Onset under dopamine agonist or under L-DOPA
- Present at the inclusion visit
- OR in the past (<6 years). For these patients, the scale of Ardouin must have been passed at the time of behavior trouble or within 3 months after its disappearance.
- Affiliation to a social security
- Signature of the consent form
Control Group
- Age upper or equal to 30 years
- Caucasian European (2 parents and 4 grandparents born in Europe)
- Parkinson's disease according to the criteria of UKPDSBB
- Time evolution of the disease than or equal to 5 years
- Having taken during its evolution a dopamine agonist dose at least equivalent to 300 mg of L-DOPA for at least 12 months.
Not having behavioral addiction
- Not current, defined as a score of 0 or 1 and at most two items with a score of 1 on all items above and addiction to L-DOPA.
- Neither passed, given authenticated by the semi-structured interview retrospective finding a score of 0 or 1 on all items hyperdopaminergic of Ardouin's scale (see above) AND no more than two items with a score of 1 and addiction to L-DOPA.
- Affiliation to a social security
- Signature of the consent form
Exclusion criteria :
Case Group
- No Parkinson's disease or atypical parkinsonian syndrome
- Taking neuroleptic except clozapine for patients with AC
- Behavioral Addiction having started BEFORE taking the antiparkinsonian treatment
Control Group
- No Parkinson's disease or atypical parkinsonian syndrome
- Taking neuroleptic included clozapine for control patients
- Behavioral Addiction having started BEFORE taking the antiparkinsonian treatment
- Patient with guardianship, deprived of his liberty by judicial decision
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
cases
Presence of ICD in PD patients (cases) is defined as a score ≥ 2 at 1 hyperdopaminegic item, or 2 scores ≥ 2 at 1 hyperdopaminergic item of the scale for assessment of behavior and mood in PD (ECMP).
|
One blood sampling during the study.
A small number (1 to 5) of markers type "tag SNPs" or "coding SNP" " (single nucleotide polymorphism, SNP) will be selected for each of the selected genes, for a total of 50 markers (representing 20 to 25 genes).
Non-silent coding SNP, that may have a functional effect, will be included as a priority.
Genotyping is carried out by the method of genotyping VeraCode Goldengate.
|
controls
Absence of ICD in PD patients (controls) is defined as a score ≤ 1 at all hyperdopaminergic items of ECMP and no more than 2 items of a score = 1.
|
One blood sampling during the study.
A small number (1 to 5) of markers type "tag SNPs" or "coding SNP" " (single nucleotide polymorphism, SNP) will be selected for each of the selected genes, for a total of 50 markers (representing 20 to 25 genes).
Non-silent coding SNP, that may have a functional effect, will be included as a priority.
Genotyping is carried out by the method of genotyping VeraCode Goldengate.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Allele frequency of 50 genetic markers (polymorphisms) will be compared between cases and controls.
Time Frame: baseline
|
baseline
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
number of patients with a diagnostic of ICD according to the MINI
Time Frame: baseline
|
baseline
|
Total UPDRS (Unified Parkinson's Disease Rating Scale) score
Time Frame: baseline
|
baseline
|
Total score of the MMSE (Mini Mental State Examination)
Time Frame: baseline
|
baseline
|
Sub scores at the temperament and Character Inventory (revised version, TCI-R)
Time Frame: baseline
|
baseline
|
Number of subject in each group with personal or familial history of addiction
Time Frame: baseline
|
baseline
|
Collaborators and Investigators
Investigators
- Principal Investigator: jean-christophe Corvol, MD, PhD, Assitance-Publique Hopitaux de Paris
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Compulsive Behavior
- Impulsive Behavior
- Parkinson Disease
- Behavior, Addictive
- Disruptive, Impulse Control, and Conduct Disorders
Other Study ID Numbers
- P100133
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Blood Sampling and DNA collection
-
Skane University HospitalLund University; Region SkaneActive, not recruitingSepsis | Critical Illness | Covid19 | Trauma | Influenza | Cardiac ArrestSweden
-
The Institute of Molecular and Translational Medicine...Cancer Research Czech RepublicCompletedCervical Cancer | Human Papillomavirus Infection | Cervical DysplasiaCzechia
-
Centre Hospitalier Universitaire DijonRecruiting
-
University Hospital, RouenUnknownMetastatic Colorectal Cancer | Circulating MarkersFrance
-
Hospices Civils de LyonRecruiting
-
University of FloridaNational Institute of General Medical Sciences (NIGMS)Recruiting
-
Hôpital Européen MarseilleRecruiting
-
Hospices Civils de LyonNot yet recruitingObesity | Sarcopenic Obesity | Bariatric Surgery | Binge Eating Disorder | Psychotropic Drugs | Syndromic Obesity | Iatrogenic ObesityFrance
-
Gamaleya Research Institute of Epidemiology and...CompletedEbola Hemorrhagic FeverRussian Federation
-
Gamaleya Research Institute of Epidemiology and...CompletedHemorrhagic Fever, EbolaRussian Federation